Skip to main content

Search

Show all results for

Home

Person

Michal Mateusz Raczy

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (3)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity

Jeffrey Alan Hubbell, Xavier Fredy René Quaglia-Thermes, Melody Swartz, Giacomo Olimpio Diaceri, Sachiko Hirosue, Laura Jeanbart, David Scott Wilson, Maria Anna Sofia Broggi, Michal Mateusz Raczy, Ruyi Wang

Fully effective vaccines for complex infections must elicit a diverse repertoire of antibodies (humoral immunity) and CD8+ T-cell responses (cellular immunity). Here, we present a synthetic glyco-adjuvant named p(Man-TLR7), which, when conjugated to antige ...

NATURE PUBLISHING GROUP2019

Synthetically glycosylated antigens induce antigen-specific tolerance and prevent the onset of diabetes

Jeffrey Alan Hubbell, Xavier Fredy René Quaglia-Thermes, Sachiko Hirosue, Giacomo Olimpio Diaceri, David Scott Wilson, Martina Damo, Michal Mateusz Raczy

Homeostatic antigen presentation by hepatic antigen-presenting cells, which results in tolerogenic T-cell education, could be exploited to induce antigen-specific immunological tolerance. Here we show that antigens modified with polymeric forms of either N ...

2019

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

Jeffrey Alan Hubbell, Melody Swartz, Seung Tae Lee, Lambert Charles François Potin, Jun Ishihara, Kazuto Fukunaga, Michal Mateusz Raczy

Cancer immunotherapy with immune checkpoint inhibitors (CPIs) and interleukin-2 (IL-2) has demonstrated clinical efficacy but is frequently accompanied with severe adverse events caused by excessive and systemic immune system activation. Here, we addressed ...

AMER ASSOC ADVANCEMENT SCIENCE2019